Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Equity Ratio (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Ratio for 8 consecutive years, with 2.11 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 28.53% to 2.11 in Q4 2025 year-over-year; TTM through Dec 2025 was 2.11, a 28.53% increase, with the full-year FY2025 number at 1.73, changed N/A from a year prior.
  • Equity Ratio was 2.11 for Q4 2025 at Outlook Therapeutics, down from 1.73 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 1.66 in Q2 2025 to a low of 2.96 in Q4 2024.